Last December we alerted you to coverage issues around closed-loop SCS. Humana, Evicore, Cigna, and UPMC all had policies that characterized the therapy as “experimental, investigational and/or unproven.” Thanks to the efforts of the Multi-Society Pain Workgroup, Evicore and Cigna both revised their policies this spring. At the end of this summer, Humana followed suit but left the language in place for commercial coverage. Earlier this month, NANS led efforts with the MPW to issue this letter to Humana, urging them to follow the example of their Medicare Advantage plan to revise their policy.
0 Comments
Your comment will be posted after it is approved.
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
March 2025
Categories |
Copyright © 2025 North American Neuromodulation Society. All Rights Reserved.
Contact Us | Privacy Policy | Refund Policy | Sitemap | Sign Up for Email |
__________________________________
111 North Wabash Avenue Suite 100-3653 Chicago, IL 60602 __________________________________
Phone: (773) 648-7845 Fax: (773) 648-7847 |